Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro and in vivo by Aday, Sezin et al.
Please cite this article in press as: Aday et al., Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro
and in vivo, Molecular Therapy (2021), https://doi.org/10.1016/j.ymthe.2021.03.015Original ArticleBioinspired artificial exosomes based on lipid
nanoparticles carrying let-7b-5p promote
angiogenesis in vitro and in vivo
Sezin Aday,1,2 Inbal Hazan-Halevy,3 Aranzazu Chamorro-Jorganes,4 Maryam Anwar,4 Meir Goldsmith,3
Nicholas Beazley-Long,5 Susmita Sahoo,6 Navneet Dogra,6 Walid Sweaad,4 Francesco Catapano,4 Sho Ozaki-Tan,4
Gianni D. Angelini,1 Paolo Madeddu,1 Andrew V. Benest,5 Dan Peer,3 and Costanza Emanueli1,4
1Bristol Heart Institute, University of Bristol, Bristol BS2 8ED, UK; 2Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA; 3Laboratory
of Precision NanoMedicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel; 4National Heart and Lung Institute, Imperial College London, LondonW12 0NN, UK;
5Biodiscovery Institute, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, NottinghamNG7 2RD, UK; 6Icahn School of Medicine at Mount
Sinai, New York, NY 10029, USAReceived 12 March 2020; accepted 15 March 2021;
https://doi.org/10.1016/j.ymthe.2021.03.015.
Correspondence: Costanza Emanueli, National Heart and Lung Institute, Imperial
College London, Hammersmith Campus, ICTEM-4 (Room 434), London W12
0NN, UK.
E-mail: c.emanueli@imperial.ac.uk
Correspondence: Dan Peer, Laboratory of Precision NanoMedicine, Tel Aviv
University, Ramat Aviv, Tel Aviv 69978, Israel.
E-mail: peer@tauex.tau.ac.ilMicroRNAs (miRNAs) regulate gene expression by post-tran-
scriptional inhibition of target genes. Proangiogenic small
extracellular vesicles (sEVs; popularly identified with the
name “exosomes”) with a composite cargo of miRNAs are
secreted by cultured stem cells and present in human biological
fluids. Lipid nanoparticles (LNPs) represent an advanced plat-
form for clinically approved delivery of RNA therapeutics. In
this study, we aimed to (1) identify the miRNAs responsible
for sEV-induced angiogenesis; (2) develop the prototype of bio-
inspired “artificial exosomes” (AEs) combining LNPs with a
proangiogenic miRNA, and (3) validate the angiogenic poten-
tial of the bioinspired AEs. We previously reported that human
sEVs from bone marrow (BM)-CD34+ cells and pericardial
fluid (PF) are proangiogenic. Here, we have shown that sEVs
secreted from saphenous vein pericytes and BM mesenchymal
stem cells also promote angiogenesis. Analysis of miRNA data-
sets available in-house or datamined from GEO identified the
let-7 family as commonmiRNA signature of the proangiogenic
sEVs. LNPs with either hsa-let-7b-5p or cyanine 5 (Cy5)-conju-
gated Caenorhabditis elegansmiR-39 (Cy5-cel-miR-39; control
miRNA) were prepared using microfluidic micromixing. let-
7b-5p-AEs did not cause toxicity and transferred functionally
active let-7b-5p to recipient endothelial cells (ECs). let-7b-
AEs also improved EC survival under hypoxia and angiogenesis
in vitro and in vivo. Bioinspired proangiogenic AEs could be
further developed into innovative nanomedicine products
targeting ischemic diseases.
INTRODUCTION
Ischemic disease in the heart and lower extremities is the leading
cause of death around the world.1,2 Stem cells (SCs), including mesen-
chymal SCs (MSCs) and bone marrow (BM) CD34-positive (CD34+)
mononuclear cells (MNCs), have been proposed to improve post-
ischemic angiogenesis and promote the recovery of blood flow to
inadequately perfused areas. However, several approaches based onThis is an open access article under the CC BY-Nautologous transplantation of proangiogenic SCs have, so far, failed
to convince when trialed clinically in ischemic patients.3,4 This could
be partially accountable to the intrinsic defects of the patient-derived
cells, which were trialed as autologous remedies in severely compro-
mised patients.
Exosomes are membrane-bound small extracellular vesicles (sEVs),
which are produced in the endosomal compartment of most eukary-
otic cells. They contribute in cell-to-cell communicationmechanisms,
underpinning homeostatic, pathogenetic, and reparative processes.5,6
Recently updated guidelines of the International Society for Extracel-
lular Vesicles (ISEV) on minimal information for studies of EVs
(MISEVs) recommend the term “extracellular vesicle” or “EV” as
the consensus generic term for lipid bilayer-delimited particles
released from the cell.7 Consequently, in the most recent literature,
exosomes are often identified as sEVs. We will adhere to this nomen-
clature when describing the endogenous nanovesicles released by cells
in this paper. Notwithstanding, in recognition of the popular use of
“exosomes,” we have adopted the term of “artificial exosomes”
(AEs) when referring to the bioinspired synthetic version we have
developed with this study. sEVs are 30150 nm in size and contain
a cargo of biologically active microRNAs (miRNAs, miRs) but also
proteins, lipids, other RNA molecules, DNA, and metabolites.
Depending on the cellular sources, sEVs have been shown to modu-
late angiogenesis in opposite directions.8,9 Similar to their parent cells,
sEVs originated from healthyMSCs and CD34+ cells have a proangio-
genic potential, which is mediated, at least in part, by miRNAs.10–15Molecular Therapy Vol. 29 No 7 July 2021 ª 2021 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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including the human pericardial fluid (PF) from cardiac surgery pa-
tients who are not suffering from ischemic disease.16 We revealed
that PF-derived sEVs promote angiogenesis and improve post-
ischemic blood flow recovery in mice by transferring miRNA let-
7b-5p (let-7b) to endothelial cells (ECs).16 Moreover, we showed
that human saphenous vein pericytes (hSVPs), which represent a
source of vascular progenitor cells, increase post-ischemic angiogen-
esis via paracrine actions.17 As part of this new study, we have char-
acterized the role of sEVs in mediating the angiogenic properties of
hSVPs and identified the miRNAs contained in the pericyte-derived
sEVs. We have also validated the proangiogenic capacity of sEVs pre-
pared from BM-MSCs in our laboratory.
Allogenic sEVs, also identified with the name of exosomes, are
currently considered to represent a more manipulable, biological
alternative to SC-based therapeutics. In fact, allogenic sEVs are not
supposed to be rejected by the host immune system after transplan-
tation.18,19 Moreover, sEVs can help in mitigating the risks of both
microvascular occlusion and cancerous growth, which are intrinsi-
cally linked with the transplant of therapeutic SCs.20 According to
https://www.clinicaltrials.gov/ , there are currently 148 clinical trials
using sEVs as therapy and/or diagnosis. Out of them, twelve studies
are testing sEVs as innovative therapeutic approaches (revised in Flo-
riano et al.21). However, the production of sEVs from SCs requires
laborious cell-handling tasks. The complexity of the cargo of endog-
enous sEVs together with the limited amount of sEVs with a repro-
ducible composition and function that can be prepared from cultured
SCs represents major challenges, which currently hamper the transla-
tion of endogenous sEVs from basic and translational research studies
to off-the-shelf “pharmaceutical products.”We reasoned that among
the individual miRNAs composing the cargo of proangiogenic
sEVs, some may be more relevant than others to ensure the proangio-
genic response. So, bioinspired AEs incorporating prototypical
proangiogenic miRNAs and devoid of anti-angiogenic and angiogen-
esis-neutral miRNAs could afford proangiogenic responses, while
ensuring feasibility for mass production.
When designing clinical-relevant AEs, an important consideration
must be given to their lipid membrane composition. Lipid nanopar-
ticles (LNPs) containing ionizable amino lipids are the most
advanced non-viral delivery platforms for negatively charged nucleic
acids, such as small interfering RNAs (siRNAs) and miRNAs. LNPs
can ensure in vivo delivery of nucleic acids with less or no immuno-
genic responses compared to viral gene delivery.22–25 A recent US
Food and Drug Administration (FDA)-approved RNAi-based
drug Onpattro (patisiran), used for contrasting polyneuropathy
induced by a genetic form of amyloidosis, is comprised of the ioniz-
able amino lipid Dlin-MC3-DMA (MC3) as part of the LNP
structure.26
In our study, we have identified the proangiogenic miRNA signature
shared by proangiogenic sEVs from 4 different human sources but ab-
sent in the sEVs that do not induce angiogenesis. This new knowledge2 Molecular Therapy Vol. 29 No 7 July 2021has been used to design a proangiogenic AE prototype encapsulating
let-7b inMC3-based LNPs. Finally, the proangiogenic potential of the
bioinspired AEs has been tested in vitro and in vivo.
RESULTS
Pericyte-sEVs are proangiogenic
We previously showed that hSVPs improve cardiac function in the
mouse myocardial infarction model through a paracrine mechanism
involving the secretion of proangiogenic miR-132.17 To investigate
the role of sEVs in this paracrine action, sEVs were isolated from
the conditioned medium (CM) of hSVPs. Nanoparticle tracking
analysis (NTA), transmission electron microscopy (TEM), and dy-
namic light scattering (DLS) analyses confirmed the presence of
sEVs in the preparations (Figures 1A and S1). By in vitro Matrigel
assay, we demonstrated that hSVP-sEVs, especially at the concen-
tration of 2.5 mg/mL, promote tubule formation in hypoxic (1%
O2) human umbilical vein ECs (HUVECs) (Figures 1B and 1C).
hSVP-sEVs also reduced caspase activity and induced proliferation
of hypoxic HUVECs compared with hSVP EV-free CM and un-
treated cell groups (Figure 1D). Both EV-free CM and hSVP-
EVs improved EC metabolism (adenosine triphosphate [ATP]
production) and viability compared with the untreated cell group
(Figure 1D).
Bioinformatic analyses reveal let-7a-5p (let-7a) and let-7b as
common proangiogenic miRNA cargos
In order to understand whether there is a common miRNA signature
for the proangiogenic sEVs, we performed computational analysis
integrating miRNA datasets obtained in-house (BM-CD34+ MNCs
and BM-MNC;14 hSVP-sEVs; PF-sEVs) (Tables S1 and S2) or avail-
able through GEO (MSCs). As non-angiogenic controls, we used
sEV miRNA datasets obtained from unsorted BM-MNCs and the
PF of ischemic patients who were operated on for coronary artery
bypass graft (CABG). Recent evidence shows that PF-sEVs from
CABG patients do not promote angiogenesis (unpublished data).
Our analysis revealed the enrichment of 21 common miRNAs in
the proangiogenic EVs (Figure 2A). Due to the importance of the
let-7 family in angiogenesis and because we detected a high expres-
sion of these miRNAs in all of the proangiogenic sEVs analyzed in
this study, we focused on the miRNAs let-7a and let-7b in the
following sections. Proangiogenic potential of sEVs prepared from
MSCs (passage 4 [P4]) was also validated in our lab (Figure S2).
Additionally, we showed that the function of MSC-sEVs was highly
dependent on the passage number of the mother cells (Figure S3).
Finally, we confirmed the presence of let-7a and let-7b in MSC-
sEVs obtained from MSCs at P4 (Figure S4).
Members of the let-7 family have proangiogenic properties
We next validated the angiogenic potential of let-7a and let-7b on
hypoxic ECs (HUVECs cultured in 1% O2). For this purpose, we
transfected HUVECs using pre-miRmolecules or scrambled controls.
Our results confirmed that scrambled controls do not affect cell
behavior in a negative way (Figure S5). To understand whether we
can improve the therapeutic capacity of these miRNAs by using
Figure 1. Characterization and activity of hSVP EVs
(A) NTA results show that hSVP EVs can be isolated from cell culture media using Exo-Spin columns (n = 3). (B) Images of Matrigel assay and evaluation of different pa-
rameters in Matrigel assay using ImageJ angiogenesis analyzer tool. hSVP EVs increase HUVEC tubule-like formation on Matrigel under hypoxic conditions (1% O2). Scale
bars, 200 mm. hSVP EV concentration: 2.5 mg/mL. (C) Evaluation of different parameters inMatrigel assay using ImageJ angiogenesis analyzer tool. (D) hSVP EVs increase cell
proliferation and decrease caspase activity compared with other groups at 2.5 mg/mL concentration. In all graphs, values are given as average ± SEM (n = 5-10). *p% 0.05,
**p % 0.01, ***p % 0.001, and ****p % 0.0001. Comparisons between EV and EV-free groups were performed with Mann-Whitney U test.
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simultaneously (co-transfection). The transfection of cells and down-
regulation of gene targets were confirmed by qPCR (Figure S6).When
the cells were transfected with either let-7a or let-7b, cell viability was
improved compared with the scramble control group (Figure S7A).
let-7a also increased cell proliferation in a dose-dependent manner
(Figure S7A). Contrarily, the co-transfection caused a decrease in
cell viability and metabolism (Figure S7B).
In vitro Matrigel assay showed that let-7a and let-7b, given either
together or via co-transfection, increase sprout formation of hypoxic
HUVECs (1% O2) on Matrigel (Figures S8–S10). However, the per-
centage of increase for different parameters was lower after co-trans-
fection of the 2 miRNAs when compared with individual transfec-
tions. Therefore, we decided to focus on let-7b alone for the next
part of the study, including the formulation of AEs and proof-of-
concept studies.AEs can be prepared by microfluidic micromixing
sEVs might have different lipidic structures depending on their parent
cells and the environmental conditions of these cells. However, it is
known that the sEV membranes have more cholesterol and less phos-
phatidylcholine in comparison with their mother cells.27,28 Similarly,
our AE formulation has more cholesterol and less phosphatidylcholine
compared with the widely used liposome formulations in the literature.
AEs encapsulating either let-7b or fluorescence (cyanine 5 [Cy5])-con-
jugated cel-miR-39-3p (cel-miR-39) (amiRNApresent inC. elegansbut
not in vertebrates) were prepared using amicrofluidicmixing system as
previously described (Figure 2B).29–32 The size of AEs was around
48.41 ± 0.45 for let-7b-AEs and 56.95 ± 3.37 for Cy5-cel-miR-39-AEs
with a narrow size distribution (polydispersity index [PDI] 
0.20.3) as measured by DLS (Figure 2B). z-potential measurements
showed a slight negative surface charge, as expected, at physiological
pH.33 TEManalysis of the LNPs indicated a globular shape and size dis-
tribution in accordance with the DLS measurements (Figure 2B).Molecular Therapy Vol. 29 No 7 July 2021 3
Figure 2. Preparation and internalization of AEs
(A) let-7a and let-7b are among the top common miRNAs in all angiogenic EVs tested. (B) miRNA-loaded AEs with the size of 50 nm can be prepared by microfluidic
micromixing. Scale bar is 200 nm in TEM picture. (C) Flow cytometry analysis of Cy5-cel-miR-39-AEs internalized by HUVECs under hypoxia (1%O2). (D and E) AEs can pass
their cargo (cel-miR-39 in the graphs) to HUVECs under both hypoxia (1% O2) and normoxia (20% O2). Relative expression was given as 2
DDCt (normalization to untreated
cell group). In all graphs, values are given as average ± SEM (n = 24).
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Flow cytometry analyses showed that AEs are internalized by
HUVECs cultured under hypoxic conditions (1% O2) (Figure 2C).
In order to measure the percentage of cells internalizing AEs, cells
were treated with Cy5-cel-miR-39-AEs. After different time points,
cells were washed to remove AEs that were not internalized or bound
and finally, analyzed by flow cytometry. Even after 4 h, almost 100%
of the cells had internalized the miRNA content of the AEs (Fig-
ure 2C). After 12 h, all cells were labeled with AE-derived, Cy5-pos-
itive cel-miR-39, and this percentage did not change up to 24 h. The
capacity of the cells to internalize the AE-deliveredmiRs was also vali-
dated by PCR for cel-miR-39-AEs (Figure 2D for normoxia and Fig-
ure 2E for hypoxia).
AEs do not induce toxicity in vascular cells
After confirming the internalization of the AEs by HUVECs, we
checked whether they cause any cytotoxicity in the potential recipient
cells. Metabolically active cells produce ATP that reflects their
viability. Hence, we used an ATP production assay to show any
possible cytotoxic effects of AEs on the cells. HUVECs were cultured
with different concentrations of AEs (both Cy5-cel-miR-39-AEs and
let-7b-AEs) up to 48 h. After 24 h, a slight decrease in the ATP pro-4 Molecular Therapy Vol. 29 No 7 July 2021duction of the cells treated with especially higher concentrations of
Cy5-cel-miR-39-AEs was observed (Figure 3A). However, after
48 h with AEs, the cells recovered and showed even higher levels of
ATP production, indicating higher cell numbers (next sections give
more detailed analysis about the behavior of the cells treated with
the AEs) (Figure 3A). Similar to the results obtained from HUVECs,
cardiac human microvascular ECs (cHMVECs) showed a slight
decrease in the ATP production at the higher concentrations of the
AEs after 24 h but recovered and increased cell number after 48 h
with AEs (Figure S11A). In hSVPs, higher concentrations of AEs
slightly decreased ATP production after 48 h with AEs (Figure S11B).
let-7b-loadedAEs improve the survival and tubule-like formation
capacities of ECs
let-7b-AEs reduced caspase activity and increased proliferation in
hypoxic (1% O2) HUVECs compared with Cy5-cel-miR-39-AEs after
48 h (Figure 3B). They slightly increased caspase-3 activity and cell
proliferation in hSVPs at 60 nM concentration and decreased cell
metabolism in cHMVECs, both cultured under 1% O2 (Figure S12).
Next, we checked whether the transfer of let-7b can increase the
angiogenic response of the cells under hypoxia (1% O2). Our results
Figure 3. The effects of let-7b-AEs on HUVEC activity
(A) AEs are not toxic for HUVECs. For toxicity studies, cells were cultured under normoxic conditions (20% O2) (n = 510). (B) let-7b-AEs decrease caspase activity and
increase proliferation in hypoxic (1%O2) HUVECs (n = 5). (C) let-7b-AEs increase sprout formation on Matrigel (n = 5). Scale bars, 200 mm. (D) let-7b-AEs pass active let-7b to
the cells and (EG) decrease let-7b gene target expression. (E) Results are given for 60 nM let-7b-AEs. Relative expression was given as 2DDCt (normalization to untreated
group in D and to cel-miR-39-AE group in EG). (DG) n = 4. In all graphs, values are given as average ± SEM, and “n” indicates completely independent biological
replicates. *p% 0.05, **p% 0.01, ***p% 0.001, and ****p% 0.0001. Comparison across subgroupswas performedwith Kruskal-Wallis test and between groupswithMann-
Whitney U test.
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2.5D Matrigel and 3D fibrin gel bead assays (Figures 3C, 4, S13, and
S14) and of cHMVECs in Matrigel assay (Figure 5). Although higher
concentrations of let-7b-AEs had a higher impact on the tubule-like
formation in HUVECs, lower let-7b-AE concentrations favored
sprout formation in cHMVECs (Figures 3C and 5).
AEs pass let-7b to ECs and decrease the expression of its gene
targets
Internalization studies clearly showed that AEs are taken up by ECs
(Figures 2C2E). However, as important as being internalized by
the target cells, AEs also must be able to pass their miRNA payload
in a functionally active form to the recipient cells (Figure 3D). Our
PCR results indicated that AEs can increase the let-7b levels in recip-
ient ECs in a time-dependent manner (Figure 3D), while subse-quently decreasing the expression of a pool of let-7b target genes (Fig-
ures 3E3G). Interestingly, let-7b-AEs could downregulate CASP3
more efficiently under hypoxic conditions than normoxic conditions
after 4 h (Figure 3E). This can explain the decrease in caspase activity
in HUVECs (Figure 3B). At 15 nM concentration, let-7b-AEs could
downregulate gene targets in HUVECs as effectively as let-7a or let-
7b Lipofectamine complexes (Figures 3F and S6).
let-7b-AEs induce formation of microvessels in vivo
To test the therapeutic effect of let-7b-AEs in vivo, we used an in vivo
Matrigel plug assay.34 Matrigel xenografts supplemented with let-7b-
AEs-transfected HUVECs increased the density of vessel-like struc-
tures in comparison to cel-miR-39-AEs and untreated cell control
groups. The plug vascularization in the let-7b-AE group was compa-
rable to the vascular endothelial growth factor (VEGF)-positiveMolecular Therapy Vol. 29 No 7 July 2021 5
Figure 4. Fibrin gel bead assay to evaluate the angiogenic
potential of let-7b-AEs in HUVECs under hypoxic
conditions (1% O2)
(A and B) Representative images (A) and quantification of sprout
length and number of sprouts (n = 4) (B) after 30 h. 30 nM let-7b-
AEs were used in the experiments. White arrows indicate the
sprouts. In all graphs, values are given as average ± SEM
(n = 510). **p % 0.01. Scale bars, 300 mm. Comparison
across subgroups was performed with Kruskal-Wallis test.
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(defined as p < 0.05) was barely missed (p = 0.0571), we could detect
a clear trend suggesting the capacity of let-7b-AEs to increase the
number of CD31+ ECs (in comparison with negative controls)
(Figure 6C).
DISCUSSION
This study has developed a prototype of clinically compatible proan-
giogenic, synthetic sEVs. Our AEs are formed by LNPs containing
ionizable amino lipids, which are the most advanced non-viral deliv-
ery platforms available for negatively charged nucleic acids, such as
miRNAs. Ionizable amino lipid is a critical component of LNP func-
tionality. Notably, the amino lipid MC3 used to build our AEs also
composes the LNP structure of a recently FDA-approved, RNAi-
based drug, Onpattro (patisiran).26 In addition, the lipidic composi-
tion of our LNP-based AEs is different from widely used liposomes
and has more cholesterol and less phosphatidylcholine as the natural
sEV exosomes.27,28 The microfluidic mixing technology based on the
NanoAssemblr device used by us is compatible with scaling up in the
good manufacturing practice (GMP) of clinical-grade nanoparticle-
based therapeutics.
As part of the current study, we have tested the in vivo angiogenic ca-
pacity of our AE prototype using the Matrigel plug model, which does
not propose biodistribution and off-targeting issues. In fact, ECs were
exposed to AEs in vitro before being mixed withMatrigel and injected
in immunocompromised mice. Future studies will employ animal
models of ischemia to test the biodistribution and therapeutic angio-
genesis potential of AEs. In details, we will trial the capacity of the let-
7b-AEs to promote the formation of functional vessels, improving
post-ischemic blood flow recovery. Such clinically relevant investiga-
tions are deemed essential to progress our translational pathway, and
we aim at developing them with a refined AE formulation. Especially,6 Molecular Therapy Vol. 29 No 7 July 2021we will functionalize the bioinspired proangiogenic
AEs to improve their targeting to ECs within
ischemic tissues. This should be feasible considering
we have recently showed that it is possible to develop
ionizable lipids for effective in vivo siRNA delivery
and gene silencing in hard-to-transfect cells, such
as T-leukocyte subsets.25 The structure of ionizable
lipids is divided into three major parts: hydrophilic
amine head group, hydrophobic lipid chain, and a
linker region, which connect these two parts. Ourrecent leukocyte-targeting study has identified the possibility to
improve siRNA-based gene silencing in a leukocyte subset by synthe-
sizing ionizable lipids based on the linkers ethanolamine, hydrazine,
and hydroxylamine.25 A similar approach can be developed to
improve in vivo targeting of LNPs carrying either siRNAs or miRNAs
to ECs.
Scientists working at sEV characterization have so far mostly focused
on the miRNA and protein content of sEVs. Although we have not
performed lipidomic analyses of the proangiogenic and antiangio-
genic sEV used in the paper, this is part of our future plans.We regard
the characterization of the lipidome of endogenous sEV to further
advance our understanding of endogenous sEV and to improve the
therapeutic use of sEVs and exosome mimetics.
ThemiRNApayload of the proangiogenicAEs developed here consists
of let-7b, which has emerged from unbiased analyses of the miRNAs
shared across proangiogenic endogenous sEVs. However, the miRNA
cargo can be easily modified in line with a personalized medicine
approach, for example, to supply tailored pro- and anti-angiogenic
therapies in a different group of patients. Moreover, the AEs could
also be modified to deliver anti-miRNAs and siRNAs to ECs.
Liposomes have been already employed to deliver miRNAs
in vivo.35,36 However, the use of miRNA-carrying liposomes tomodu-
late angiogenesis in vivo is still very limited, with the absence of major
reports in the recent literature. In vivo biodistribution of liposomes
has been shown to be significantly influenced by changes in their sur-
face potentials.37 By contrast, our formulation offers the advantage of
maintaining the distribution profile based on the design of the head-
group moieties and despite differences in surface potentials. This is
a significant advantage for RNA-based therapeutics because RNA
molecules are negatively charged, and addition of different RNA
Figure 5. Matrigel analysis of cHMVECs treated with cel-miR-39-AEs or let-7b-AEs under hypoxic conditions (1% O2)
(A) Representative Matrigel photos. Scale bars, 200 mm. (B and C) Analysis of different parameters by ImageJ angiogenesis analyzer. In all graphs, values are given as
average ± SEM (n = 5). *p% 0.05, **p% 0.01, ***p% 0.001, and ****p% 0.0001. Comparisons between cel-miR-39-AE and let-7b-AE groups were performed with Mann-
Whitney U test.
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ever, in our formulation, z-potential is mostly affected by the compo-
sition of LNP structural lipids and less from the encapsulated RNA.
Endogenous AEs, which are produced from different types of SCs,
share the therapeutic angiogenic potential of their parent cells, thus
considered as “SCs without the cells.”8 Here, we have expanded the
number of SC and progenitor types able to secrete proangiogenic
sEVs by demonstrating that pericytes produce highly proangiogenic
sEVs in culture. Moreover, we have confirmed the angiogenic poten-
tial of MSC-sEVs.38,39 In addition to their proangiogenic capacity,
MSC-sEVs can reduce infarct size,40,41 and they have also been shown
to increase ATP levels, decrease oxidative stress, and activate prosur-
vival pathways in a rodent model of myocardial infarct and ischemia/
reperfusion injury.42 Furthermore, MSC-sEVs have an attractive
immunomodulatory capacity, inducing immunoregulatory, anti-
inflammatory monocyte phenotypes, as evidenced in studies on
different bronchopulmonary disease models.43,44 Notwithstanding,
a restriction on endogenous sEV utilization for therapeutic applica-tion is their limited secretion from SCs. This bottleneck is especially
relevant for MSCs, which have a limited expansion capacity and
become senescent after only a few passages in culture.45 It was already
known that sEVs derived from senescent SCs have impaired regener-
ative capacity compared to young cells,45 and we have directly vali-
dated this in our study, where we have detected dramatic differences
in the EC survival and proliferative responses induced by sEVs pre-
pared from MSCs at different passages (P4 versus P78). This issue,
however, does not prevent deriving information on the miRNA cargo
of the highly functional sEVs produced by young MSCs and then
using such knowledge for designing AE counterparts.
To decide on the miRNA payload to be used to design our prototype
of angiogenic AEs, we have bioinformatically integrated sEV-miRNA
datasets from both cultured human cells, including MSCs, pericytes,
BM-CD34+ MNCs, and total BM-MNCs14,15 and a human biological
fluid in direct contact with the heart, the PF. We already showed that
the PF of non-ischemic patients contains sEVs with high proangio-
genic potential in vitro and in a murine limb ischemia model.16Molecular Therapy Vol. 29 No 7 July 2021 7
Figure 6. The let-7b-AE group has a tendency to increase HUVEC survival in the Matrigel plug assay in vivo
(A and B) Representative images (A) and quantification of number of vessel-like structures per image (B). One-way ANOVA with Bonferroni post hoc test was used for
statistical analysis. **p% 0.01. (C) Quantification of number of nuclei/CD31 area. Comparison between untreated and let-7b-AE groupswas performedwithMann-Whitney U
test (p = 0.0571). In CD31 images, pseudocolor was used (red channel shown in green) to make cells easier to see. All data are expressed as mean ± SEM, n = 4. Scale bars,
50 mm.
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ischemic heart disease are unable to stimulate angiogenesis responses
in recipient ECs (unpublished data). The addition of miRNA datasets
from PF-sEVs to this study is justified by our interest in understand-
ing the proangiogenic miRNA cargo of sEVs, which are already in
the position to interact with ECs of the heart, an organ that could
particularly benefit from AE-mediated proangiogenic therapies.
Our computational analyses have also included the miRNA cargo
of PF-sEVs from patients with severe ischemic heart disease requiring
CABG surgery. The sEV-miRNAs extracted from the PF of CABG pa-
tients have been assumed here not to be significant contributors to
in vivo autonomous reparative angiogenic responses and treated as
“non-proangiogenic” controls in our miRNA analyses. let-7b has
emerged from unbiased bioinformatic analyses developed using pre-
defined filter criteria for miRNA selection. It is, however, noteworthy
that the role of let-7b in mediating the in vitro angiogenic potential of
PF-sEVs was already demonstrated by us.16 Moreover, the capacity of
other members of the let-7 family, but not let-7b, to regulate ocular
angiogenesis has been recently established using a transgenic mouse
model, overexpressing let-7a, -7d, and -7f.46
We have analyzed the mRNA expressional changes induced by the
AE-let-7b in ECs to characterize the functional capacity of AE-
derived miRNA to inhibit the miRNA target genes in recipient cells.
That being said, it is possible that the deregulation of some of these8 Molecular Therapy Vol. 29 No 7 July 2021genes targeted by let-7b contributed to the survival and angiogenic
responses observed in ECs treated with AE-let-7b. In details, the
apoptotic protease-activating factor-1 (APAF1) is a key molecule in
the mitochondrial pathway of apoptosis. Its inhibition by let-7b-5b
could therefore contribute to the prosurvival effect of this miR.47
The loss of STARD-13 (StAR-related lipid transfer [START] domain
containing 13), also known as (aka) DLC2 (deleted in liver cancer 2),
has been associated with angiogenic responses.48 Finally, CTNNB1
(catenin beta 1, aka b-catenin), as part of theWnt/b-catenin pathway,
can either promote or inhibit angiogenesis.49 The Wnt receptor Friz-
zled-4 (FZD4) has also a dual impact on angiogenesis regulation.50,51
In conclusion, we have provided the evidence that the let-7 family of
miRNAs is highly expressed in 4 different types of proangiogenic
sEVs derived from different sources and that the incorporation of
let-7b into LNP-based AEs allows the efficient delivery of this miRNA
to ECs regulating functional responses, which lead to angiogenesis.
Our results suggest the potential of AEs as a platform in therapeutic
angiogenesis.
MATERIALS AND METHODS
Clinical sample collection and processing
The collection and use of clinical leftover samples from cardiac sur-
gery patients complied with the ethical principles stated in the Decla-
ration of Helsinki and the Human Tissue Act and were covered by
www.moleculartherapy.org
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(NRES; Research Ethics Committee [REC] references 13/OL/1687
and 10/HO107/63). The collection of long saphenous vein leftovers
from CABG surgery complied with the principles stated in the
Declaration of Helsinki and was approved by the Bath REC (reference
06/Q2001/197). Patients gave written, informed consent for inclusion
in the study.
Preparation of PF-sEVs
PF samples from patients undergoing aortic valve replacement (AVR)
and CABG were collected immediately after opening of the pericar-
diumusing a 20-mL syringe and transported to the laboratory in a ster-
ile 50-mL container. Information for the patients used in this study is
given in Table S3. PF was centrifuged at 13,500 g, room temperature
(RT), for 5min to deplete miRNA-rich platelets. The platelet-free fluid
was centrifuged at 13,500 g, RT, for 5 min to remove any remainder
of cells. Processed samples were stored at 80C until use. EVs were
isolated from the PF of the patients undergoing AVR and CABG sur-
geries (n = 4 in each group) using Exo-Spin columns from Cell Guid-
ance Systems (Cambridge, UK). Briefly, 200mL PFwas filtered through
a sterile 0.22-mm filter (MerckMillipore, Burlington, MA, USA) into a
fresh tube. Then, the filtered PF was applied onto the Exo-Spin col-
umns, and EV separation was performed as described by themanufac-
turer. EVs isolated from 200 mL PF and concentrated in 100 mL PBS
were used in RNA isolation without any further modification.
Preparation of sEVs from human BM-CD34+ cells
BM-MSCs were purchased from Rooster Bio (Frederick, MD, USA).
Please see Major Resources (Table S4) for more information about
BM-MSCs. Cells at P4 to P8 were seeded in T225 flasks (Cellbind
Flasks, Corning, NY, USA) containing 45mL of a-minimum essential
medium (MEM; Sigma-Aldrich, St. Louis, MO, USA) with 10% fetal
bovine serum (FBS; seeding density of 2.93.7  103 cells/cm2).
Upon reaching 98%–99% confluency, cells were washed three times
with PBS and incubated for 38 h in 35 mL of a-MEM serum-free me-
dium. EVs were isolated from a starting volume of 280 mL MSC CM.
Briefly, medium was centrifuged (at 300  g for 10 min at RT;
2,000  g for 20 min at +4C, and 13,000  g for 30 min at +4C),
filtered through a sterile 0.22-mm filter (Millipore Express polyether-
sulfone [PES] membrane; Millipore, Burlington, MA, USA), and
concentrated to a final volume of 500 mL with Centricon Plus-70 Cen-
trifugal Filter Units 100 molecular weight cut-off (MWCO; Millipore,
Burlington, MA, USA), according to the manufacturer’s protocol.
sEVs were subsequently isolated by size-exclusion chromatography
with the EVoriginal/35 nm Izon column (Izon Science, Christchurch,
New Zealand). sEV-containing fractions (79) were pulled together
and concentrated to a final volume of 200 mL with the Amicon
Ultra-4 Centrifugal Filter Units 10 MWCO (Millipore, Burlington,
MA, USA). The output of sEV preparation was quantified with the
NanoSight NS300 system at 1:100 concentration. A final concentra-
tion of 1.9 1010 particles/mL was detected. Total protein concentra-
tion was determined using Micro bicinchoninic acid (BCA) protein
assay (BosterBio, Pleasanton, CA, USA) according to the manufac-
turer’s protocol.Culture of hSVPs and isolation of sEVs
Intravascular hSVPs were isolated from saphenous veins that were
leftovers from CABG surgery, as described.17,52 For the isolation of
the sEVs, pericytes (P6) were seeded in complete EGM-2 medium,
and after the attachment of the cells, the medium was replaced by
EGM-2 (without SingleQuot FBS; Lonza, Basel, Switzerland) contain-
ing 2% sEV-depleted FBS from Gibco (Waltham, MA, USA). Pericyte
CM was collected from confluent pericyte cultures every 3 days and
centrifuged at 300 g for 10 min to remove cells. Then, the superna-
tant was transferred into a new centrifuge tube and spun at 16,000 g
for 30 min to remove any remaining cell debris. The supernatant was
transferred into a new Falcon and kept at80C until use. On the day
of the isolation, supernatants were thawed on ice, and then sEV isola-
tion was performed from 5 mL cell culture medium using Exo-Spin
columns from Cell Guidance Systems (Cambridge, UK) according
to the manufacturer’s instructions. Total protein concentration was
determined using Micro BCA protein assay (Thermo Fisher Scienti-
fic, Waltham, MA, USA) according to the manufacturer’s protocol.
The amount of EVs used in the experiments is given as “mg EV pro-
tein/mL” (“mg/mL” in graphs). At difference with the sEV derived
from the PF and MSC, pericyte-derived sEVs were not previously
studied. Therefore, we have characterized them by combining TEM,
NTA, and DLS as described in the next sections.
sEV TEM analyses
Frozen exosome pellet was brought to RT. Equal volumes of exo-
somes and 3% glutaraldehyde were mixed and kept at RT for 1 h.
Osmium tetraoxide was added to the exosome solution and was
kept at RT for 1 h. Final exosome solution was transferred to a for-
mvar-coated TEM grid (EMS FCF100-Cu). The grids were observed
under the electronmicroscope at 80 kV and stored in appropriate grid
storage boxes for future use.
sEV NTA analyses
The NTA apparatus NanoSight NS300 (Malvern Panalytical, Mal-
vern, UK), with NTA software version 3.2 (Malvern Instruments),
was employed to characterize the size and concentration of the
sEVs isolated from the pericyte CM.53 For the analyses, sEVs were
diluted 5 times in Dulbecco’s phosphate-buffered saline (DPBS).
Then, each sample was filtered using 0.22 mm Millex syringe filter
unit (Millipore, Burlington, MA, USA) and injected into the flow
cell of the NanoSight NS300. Once loaded, the sample was passed
through the system using a syringe pump at a rate of 50 arbitrary units
(a.u.), decreased gradually through 500, 300, 200, and 100 a.u. Four
consecutive videos were recorded for each pericyte line (each
obtained from a different donor), and 3 lines were used to calculate
particle concentration per milliliter.
sEV DLS analysis
For the DLS analysis, the isolated sEVs were diluted to 1 mL using
PBS (filtered via 0.1 mm filter) containing 2 mM ethylenediaminete-
traacetic acid (EDTA). Dynamic light-scattering measurements
were performed with a Zetasizer Nano ZS (Malvern Instruments,
Worcestershire, UK). Intensity, volume, and distribution data forMolecular Therapy Vol. 29 No 7 July 2021 9
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of six. At least three different measurements were performed for
the analysis. Data were presented as size distribution by number
(percent) enrichment.
RNA isolation and qPCR analysis
Total RNA was extracted from cells and sEVs using the miRNeasy
Mini Kit (QIAGEN, Hilden, Germany), according to the manufac-
turer’s instructions.
For the determination of miRNA expression in hSVP-sEVs and PF-
sEVs, a synthetic analog of non-human cel-miR-39 (QIAGEN, Hil-
den, Germany) was spiked (in 10 mL of a 5-fmol/mL stock) to
normalize RNA extraction efficiency. cDNA synthesis and real-time
qPCR were performed using a miRCURY LNA Universal RT micro-
RNA PCR system (Exiqon, Denmark). cDNA products were trans-
ferred to the microRNA PCR Human Panels (I + II; version 4) and
run using the QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). EV miRNA data are presented
in Table S1 (PF EVs) and Table S2 (hSVP EVs) and have been depos-
ited in GEO (GEO: GSE118103 and GSE118855).
2.5 mg MSC-sEV was used to determine the expression of let-7a and
let-7b. For this purpose, synthetic analog of the non-human cel-miR-
39 was spiked (in 10 mL of a 5-fmol/mL stock) to normalize RNA
extraction efficiency. Mature let-7b, let-7a, and cel-miR-39 levels
were analyzed using miRNA TaqMan Assays and TaqMan
MicroRNA Reverse Transcription Kit (Life Technologies, Carlsbad,
CA, USA). TaqMan miRNA primer IDs are given in Table S5.
miRNA expression was normalized with U6 small nuclear RNA
(snRNA), and relative expression was calculated using the 2DCT
(2[(Ctsample  Cthousekeeping)]) method.
To determine the expression of the miRNAs in the cells, reverse tran-
scription of individual miRNAs was performed using the TaqMan
miRNA Reverse Transcription Kit and miRNA-specific stem-loop
primers (Table S5) (Thermo Fisher Scientific, Waltham, MA, USA).
qPCR was performed using 2  Universal PCR Master Mix with
No AmpErase UNG (Thermo Fisher Scientific, Waltham, MA,
USA) and analyzed using the QuantStudio 6 Flex Real-Time PCR Sys-
tem (Applied Biosystems, Foster City, CA, USA). miRNA expression
was normalized with U6 snRNA, and relative expression was calcu-
lated by normalizing data using reference samples (scrambled
miRNA group for cells transfected with Lipofectamine containing
let-7a, let-7b, or let-7a + let-7b or cel-miR-39-AE group for cells
transfected with let-7b-AEs; 2DDCt, please see below).
For mRNA analysis, cDNA obtained using the High-Capacity RNA-
to-cDNA Kit (Thermo Fisher Scientific, Waltham, MA, USA) was
amplified by real-time qPCR. SYBR Green primers (from Sigma, St.
Louis, MO, USA) and PowerUp SYBR Green Master Mix (Thermo
Fisher Scientific, Waltham, MA, USA) were used to analyze the
gene expression. The 2DDCt method was used for the quantification
of target gene expression relative to the scrambled miRNA group (for10 Molecular Therapy Vol. 29 No 7 July 2021cells transfected with Lipofectamine containing let-7a, let-7b, or let-
7a + let-7b) or cel-miR-39-AE group (for cells transfected with let-
7b-AEs). After calculation of DCT using the formula DCT = CT
(target gene)  CT (GAPDH), DDCT was calculated: DDCT =
DCT (target sample)  DCT (a reference sample). Then, relative
expression was given as 2[(DCtsample  DCtreference)] (2DDCt). Primer
sequences are given as supporting information (Table S6). Gene tar-
gets of synergistic miRNA regulation for let-7a and let-7b were deter-
mined using TriplexRNA database54,55 and given in Table S7.
Procurement and bioinformatic analyses of miRNA datasets
from proangiogenic sEVs and non-proangiogenic sEVs
For analysis of miRNAs enriched in proangiogenic sEVs, we used the
following datasets: (1) miRNA array data of proangiogenic sEVs from
the proangiogenic BM-CD34+ fraction of human BMMNCs (CD34+
sEVs) and from control total BM-MNC (cells inert for what concerns
angiogenesis);14 (2) miRNA array data of MSC-sEVs that also have
proangiogenic effects (GEO: GSE71241); (3) miRNA qPCR panels
of PF EVs, which we previously proved to be angiogenic16 (GEO:
GSE118103); and (4) miRNA qPCR panels of hSVP EVs that were
also determined as “proangiogenic” as part of this study (vide supra)
(GEO: GSE118855). In this analysis, miRNAs (1) present in proan-
giogenic sEVs, only (absent in angiogenesis-neutral sEVs from:
BM-MNC and CABG-PF) and (2) of which expression is higher
than inert BM-MNC EVs or CABG EVs were taken into consider-
ation. After determination of miRNAs, Venn diagrams were prepared
using the VENNY interactive tool (https://bioinfogp.cnb.csic.es/
tools/venny/index.html).
AE production
AEs were prepared using microfluidic micromixture (Precision
NanoSystems). 1 vol of a mixture of ionizable lipid (MC3),29 with
cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
and dimyristoyl glycerol-polyethyleneglycol (DMG-PEG), at a molar
ratio of 50:38:10:2, at 9.64 nM total lipid concentration in ethanol and
3 vol of miRNA (1:16 w/w miRNA to lipid) in an acetate buffer (pH
4.0), was injected into the micromixer in a controlled flow rate
(0.5 mL/min for ethanol and 1.5 mL/min for buffer) to form uniform
AEs. miRNA sequences used in the preparation of AEs are given in
Table S8. The resultant mixture was dialyzed overnight against PBS
(pH 7.4) to remove ethanol. AE size distribution was determined by
DLS and confirmed by NTA (both fromMalvern Instruments). z-po-
tential was determined by Nano ZS z-Sizer (Malvern Instruments).
For size measurements, LNPs were diluted 1:20 in PBS. For z-poten-
tial measurements, AEs were diluted 1:200 in double-distilled water.
Size and shape of AEs were analyzed by TEM (Philips Tecnai F20 field
emission TEM operated at 200 kV). For this, AEs diluted in PBS were
placed on a formvar/carbon-coated copper grid, air dried, and stained
with 2% (w/v) aqueous uranyl acetate.
Determination of uptake of AEs in HUVECs by flow cytometry
HUVECs were seeded onto 1% gelatin-coated cell culture plates and
incubated overnight at 37C with 5% CO2 for cell attachment and re-
covery. For internalization studies, HUVECs were incubated with
www.moleculartherapy.org
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30 nMmiRNA concentration). Internalization studies were performed
under hypoxic conditions (1%O2), and cells were transfectedwith AEs
for 4, 8, 12, and 24 h. After transfection of the cells with different con-
centrations (15 and 30 nM miRNA concentration) of AEs, cells were
detached using TrypLE Express (Thermo Fisher Scientific, Waltham,
MA, USA), centrifuged at 300  g for 5 min, and stained with the
Zombie Yellow Fixable Viability Kit according to the manufacturer’s
instructions (BioLegend, San Diego, CA, USA). Finally, the cells
were fixated using 4% paraformaldehyde (Sigma-Aldrich, St. Louis,
MO, USA) and suspended in PBS. Novocyte Flow Cytometer and
NovoExpress software (both from ACEA Biosciences, San Diego,
CA, USA) were used for the acquisition and analysis of the data.
In vitro functional studies
Please see Major Resources (Table S4) in the Supplemental informa-
tion for information regarding HUVECs and cHMVECs. Cells were
transfected with EVs or individual pre-miRs or scramble miRNAs
or AEs. In detail, cells were seeded onto 1% gelatin-coated cell culture
plates and incubated overnight at 37C with 5% CO2 for cell attach-
ment and recovery. For Matrigel assay and RNA isolation, HUVECs
were seeded as 4  104 cells/well in 24-well plates or as 8  104 cells/
well in 12-well plates. For cell viability, metabolism, and proliferation
experiments, cells were seeded as 1  104 cells/well in 96-well plates.
After overnight incubation at 37C with 5% CO2, cells were trans-
ferred to a hypoxia incubator (1% O2) to mimic ischemic conditions.
Following 1 day’s incubation under hypoxic conditions, cells were
transfected using different test substances (EVs, pre-miRs, or AEs).
Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA) was
used according to the manufacturer’s protocols for the transfection
with pre-miRs or scramble miRNAs. Overexpression of individual
let-7 family members was achieved by transfection of cells with
7.530 nM pre-miRs (Ambion, Carlsbad, CA, USA). 7.530 nM
pre-miR scramble control from Ambion was used as control in all
transfection experiments. For AE studies, AEs with 1560 nM
miRNA were used unless otherwise stated. After an additional
2 days of incubation under hypoxic conditions (1% O2), analyses of
the cells were performed as described in the sections below. Only
the toxicity studies of AEs were performed under normoxic (20%
O2) conditions.
Cell metabolism, caspase activity, and cell viability
measurements
Cell metabolism was determined by the CellTiter-Glo ATP produc-
tion assay and apoptosis by Caspase-Glo 3/7 assay (all from Promega,
Madison, WI, USA) according to the manufacturer’s instructions
with modifications. For CellTiter-Glo and Caspase-Glo 3/7 assays,
50 mL of PBS and 50 mL CellTiter-Glo or Caspase-Glo 3/7 reagents
were mixed in each well and incubated at RT for 5 min on an orbital
shaker to induce cell lysis. PBS without cells, with CellTiter-Glo or
Caspase-Glo 3/7 reagents, was used as a blank control.
Cellular viability was determined by the RealTime-Glo MT Cell
Viability Assay as described by the manufacturer without any modi-fications. Briefly, 2 RealTime-Glo reagent was prepared by diluting
the MT cell viability substrate and NanoLuc enzyme in 37C cell cul-
ture medium to a 2 concentration for each reagent. To prepare 1 mL
of 2 RealTime-Glo reagent, 2 mL of MT cell viability substrate
(1,000) and 2 mL of NanoLuc enzyme (1,000) were added to
996 mL of cell culture medium. 2 RealTime-Glo reagent was added
onto the cells and incubated for 1 h at 37C, 5% CO2. Cell culture me-
dium without cells, with 2 RealTime-Glo reagent, was used as blank
control. For all experiments, the measurements were done using a
GloMax-96 microplate luminometer (Promega, Madison, WI, USA).
Cell proliferation measurements
The cell proliferation ELISA, bromodeoxyuridine (BrdU; colori-
metric) (Roche, Mannheim, Germany), was used according
to the manufacturer’s instructions for the determination of cell
proliferation. Briefly,10 mL/well BrdU labeling solution (final
concentration:10 mM BrdU) was added, and cells were re-incubated
for an additional 4 h at 37C. After removal of the labeling medium
and drying of the labeled cells, plates were stored for up to 1 week
at +4C. 200 mL/well FixDenat solution was added to the cells and
incubated for 30 min at RT. FixDenat solution was removed, and
100 mL/well anti-BrdU-POD working solution was added into the
plates. Following incubation for 90 min at RT, antibody conjugate
was removed by flicking off, and wells were washed three times
with 200 mL/well washing solution (PBS, 1). Washing solution
was removed, 100 mL/well substrate solution was added, and plates
were incubated at RT until color development is sufficient for photo-
metric detection (530 min). Finally, 25 mL 1 M H2SO4 (R&D Sys-
tems, Minneapolis, MN, USA) was added to each well, and plates
were incubated for approximately 1 min on the shaker at 300 rpm.
Absorbance of the samples was measured at 450 nm using a Dynex
Opsys MR Microplate Photometer (Aspect Scientific, Cheshire, UK).
2.5D-Matrigel in vitro assay
Angiogenesis m-slides (IBIDI, Munich, Germany) were coated with
Matrigel (10 mL per well; without dilution; BD Biosciences, San Diego,
CA, USA) and incubated for 30 min at 37C. Transfected (for 2 days)
and non-transfected HUVECs or cHMVECs were detached using
TrypLE Express (Gibco, Waltham, MA, USA), suspended in EGM-
2medium, and seeded on top of polymerized Matrigel at a concentra-
tion of 1 105 cells/mL in 50 mLmedium. Cells were incubated under
hypoxia conditions (1%O2) with 5%CO2. Pre-chilled pipette tips and
slides were used in these experiments, and Matrigel was kept on ice to
prevent polymerization. Sprout formation was evaluated by phase
contrast microscopy (Zeiss Axiovert 200; Carl Zeiss, Oberkochen,
Germany) 6 h after the cell seeding.
3D-fibrin gel bead in vitro assay
3D-fibrin gel bead assay was performed as described previously.56
Briefly, 1  106 HUVECs were mixed with 2,500 Cytodex-3 beads
(GE Healthcare, Uppsala, Sweden) in EGM BulletKit for 4 h at
37C. Then, beads were transferred to T25 flask in 5 mL of EGM Bul-
letKit and left overnight. The following day, the coated beads were re-
suspended in fibrinogen solution (2.0 mg/mL fibrinogen, 0.15 U/mLMolecular Therapy Vol. 29 No 7 July 2021 11
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of 200 beads/mL. 0.625 U/mL of thrombin was added per well of a
24-well plate followed by 0.5 mL of the fibrinogen/bead suspension
per well (1 mg fibrinogen per well). The plate was then placed at
37C for 1015 min. After clot formation, 1 mL of EGM BulletKit
was added to each well. After 30 h in hypoxia (1% O2), angiogenic
sprouting was quantified by measuring cumulative sprout length
and branches using NIH ImageJ software. For this analysis, pictures
were taken using a Nikon Eclipse TE200 inverted microscope at
4magnification. For each experiment, at least 10 spheroids per trip-
licate well were analyzed after 30 h.In vivo Matrigel plug assay
Please see Major Resources (Table S4) in the Supplemental informa-
tion for information about animals and antibodies used in Matrigel
plug assay. Matrigel was thawed at 4C overnight before implanta-
tion. 1  105 HUVECs were resuspended in 100 mL of medium
without FBS and mixed with 100 mL of Matrigel on ice (2 times dilu-
tion of Matrigel). The Matrigel mix was then implanted subcutane-
ously into nude mice (Crl:CD1-Foxn1nu; Charles River, UK). After
7 days, mice were sacrificed, and Matrigel plugs were harvested for
immunohistochemistry. Matrigel plugs were embedded in optimal
cutting temperature (OCT) prior to staining and fixated using 4%
paraformaldehyde. 20 mm cryosections were stained with anti-
CD31 antibody (Abcam; cat #] ab28364; dilution factor: 1:50).
Alexa Fluor 647 AffiniPure donkey anti-rabbit immunoglobulin
G (IgG) (heavy + light chains [H+L]) antibody from Jackson
ImmunoResearch was used as a secondary antibody (cat #711-605-
152; dilution factor: 1:200). The nuclei of the cells were stained with
40,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Slides were
observed under a fluorescence microscope (Zeiss LSM-780 confocal
microscope). 4 high-power fields/mouse (20 magnification) were
captured, and the number of nuclei/CD31 area was calculated using
ImageJ software. For the analysis of images, background correction
was done using ImageJ. Briefly, HiLo LUT option was chosen to
display zero values as blue and white values (pixel value 255) as
red. Background was removed with the “Brightness/Contrast” com-
mand by slowly raising the “Minimum” value until most of the back-
ground is displayed blue. In the figures, CD31 images have pseudo-
color (red channel was shown in green) to make cells easier to see.Statistical analysis
Comparisons between two different conditions were assessed using
an unpaired t test. If the normality test failed, the Mann-Whitney
test was performed. Experiments with three or more experimental
groups were compared by one-way analysis of variance (ANOVA).
GraphPad Prism software (San Diego, CA, USA; http://www.
graphpad.com) was used for the statistical analysis. Results were
considered significant when p <0.05. Data are shown as mean ± SEM.SUPPLEMENTAL INFORMATION
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